Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers

NEXT STORY
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)
PREV STORY
In Vitro Diagnostics Market Size to Hit US$ 123.7 Bn by 2030
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting

Potent anti-Candida activity shown in vaginal acidic pH and high penetration into vaginal tissue ...

author_avatar
NASDAQ Market News

SHIRE ANNOUNCES EARLY RESULTS OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES

SHIRE ANNOUNCES EARLY RESULTS OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING ...

author_avatar
NASDAQ Market News

UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, March ...

author_avatar
NASDAQ Market News